Case Study · Multiple Sclerosis / mRNA Vaccine Response
Vaccine-naive MS patients.
12 specialist sites delivered on a compressed timeline.
How AcceleTrial identified specialist MS sites with the right patient profile for a niche mRNA vaccine response trial, with documents collected at a 50% faster rate.
The Challenge
A niche patient profile.
A tight timeline. A new modality.
Finding sites with the right combination of MS expertise and access to vaccine-naive patients for an mRNA trial required a precision approach that traditional site identification methods could not deliver quickly enough.
The sponsor needed 10 clinical sites with access to vaccine-naive MS patients, a specialized sub-population requiring both MS clinical expertise and specific patient history criteria.
The team needed to communicate with a large volume of clinical sites and execute CDAs and Feasibility Questionnaires on an accelerated schedule, with no room for slow document cycles.
Sites needed to be activated quickly and efficiently to exceed the sponsor's targeted timelines. For a novel mRNA study with a niche patient group, every lost week created compounding risk.
The Solution
12 MS sites.
50% faster document collection.
Using AcceleTrial, LINEA System identified 12 sites with specific MS clinical expertise and the right patient access profile. The platform collected all necessary study documents at a 50% faster rate than standard timelines.
LINEA provided key contributing clinical sites and investigators evaluated against a rigorous set of qualification criteria, ensuring each site was genuinely prepared to enroll the right patients for this novel mRNA trial.
Outcomes
Specialist sites found.
Target exceeded.
12 specialist MS sites with vaccine-naive patient access delivered against a target of 10.
All necessary study documents collected at a 50% faster rate through AcceleTrial's automated workflow.
7 LINEA-sourced sites selected for inclusion in the mRNA vaccine response study from the 12 identified.
LINEA identified 20% more sites than the sponsor's requirement, providing a qualified reserve in a narrow patient population.
Get the Full Story
Download the case study
or see AcceleTrial live
Get the one-page PDF summary or request a personalized demo using your protocol and therapeutic area.